Home / Recalls / Sandoz, Inc / D-0127-2020

D-0127-2020 Class II Terminated

Recalled by Sandoz, Inc — Princeton, NJ

Recall Details

Product Type
Drugs
Report Date
October 16, 2019
Initiation Date
September 23, 2019
Termination Date
July 14, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
100,314 bottles

Product Description

Sandoz Ranitidine Hydrochloride Capsules 150mg 60 Capsules Rx Only Manufactured by Sandoz Inc. Princeton, NJ Product of India NDC 0781-2855-60

Reason for Recall

CGMP Deviations: Detection of a trace amount of an unexpected impurity, N-nitrosodimethylamine (NDMA).

Distribution Pattern

U.S. Nationwide

Code Information

HC9266 4/30/2020 HD1865 4/30/2020 HP9441 9/30/2020 JK7994 8/31/2021 JK8659 8/31/2021

Other recalls by Sandoz, Inc

  • D-0651-2025 Class II — Cyclophosphamide Injection 500 mg/5 mL (100 mg/mL), Hazardous Drug, Rx Only, Ste (September 5, 2025)
  • D-0626-2025 Class II — Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension Rx Only, For Use in Ea (August 13, 2025)
  • D-0569-2025 Class I — Cefazolin for Injection, USP, 1 gram per vial, Sterile, For Intramuscular or Int (June 27, 2025)
  • D-0570-2025 Class I — Buffered Penicillin G Potassium for Injection, USP 20,000,000 Units (20 million (June 27, 2025)
  • D-0753-2022 Class II — Orphenadrine Citrate Extended-Release Tablets, USP 100 mg, Rx Only, 100 Tablets, (March 21, 2022)
  • D-0286-2022 Class I — Enoxaparin Sodium Injection, USP, 40 mg/0.4 mL, Single-Dose Syringes with Automa (November 17, 2021)
  • D-1259-2020 Class II — Infuvite PEDiatric Pharmacy, kit in 1 carton (40 mL fill in a 50 mL) vial 1 an (April 21, 2020)
  • D-0162-2020 Class III — Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension, Rx On (October 17, 2019)
  • D-0163-2020 Class III — Gatifloxacin Ophthalmic Solution 0.5%, For Use in the Eyes Only, Rx Only, Steril (October 17, 2019)
  • D-0161-2020 Class III — Bimatoprost Ophthalmic Solution 0.03%, Rx Only, For Topical Application to the U (October 17, 2019)